Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

784 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exemestane for breast-cancer prevention.
Hanaoka M, Takano T, Kawabata H. Hanaoka M, et al. Among authors: kawabata h. N Engl J Med. 2011 Sep 15;365(11):1056-7; author reply 1057-8. doi: 10.1056/NEJMc1108287. N Engl J Med. 2011. PMID: 21916645 No abstract available.
Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
Tanioka M, Sasaki M, Shimomura A, Fujishima M, Doi M, Matsuura K, Sakuma T, Yoshimura K, Saeki T, Ohara M, Tsurutani J, Watatani M, Takano T, Kawabata H, Mukai H, Naito Y, Hirokaga K, Takao S, Minami H. Tanioka M, et al. Among authors: kawabata h. Breast. 2014 Aug;23(4):466-72. doi: 10.1016/j.breast.2014.03.008. Epub 2014 Apr 16. Breast. 2014. PMID: 24742606 Free article.
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y, Shimizu C, Hamada A, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yamamoto H, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y. Tanabe Y, et al. Among authors: kawabata h. Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186. doi: 10.1007/s00280-017-3314-9. Epub 2017 Apr 26. Cancer Chemother Pharmacol. 2017. PMID: 28447211
Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y, Tanabe Y, Tamura N, Ogura T, Kondoh C, Miura Y, Yoshimura K, Kawabata H, Takano T. Ozaki Y, et al. Among authors: kawabata h. Breast Cancer. 2018 May;25(3):343-349. doi: 10.1007/s12282-018-0836-x. Epub 2018 Jan 22. Breast Cancer. 2018. PMID: 29357022 Free PMC article.
A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
Takano T, Tsurutani J, Takahashi M, Yamanaka T, Sakai K, Ito Y, Fukuoka J, Kimura H, Kawabata H, Tamura K, Matsumoto K, Aogi K, Sato K, Nishio K, Nakagawa K, Saeki T. Takano T, et al. Among authors: kawabata h. Breast. 2018 Aug;40:67-75. doi: 10.1016/j.breast.2018.04.010. Epub 2018 Apr 23. Breast. 2018. PMID: 29698927 Clinical Trial.
Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review.
Takahashi M, Ozaki Y, Kizawa R, Masuda J, Sakamaki K, Kinowaki K, Umezu T, Kondoh C, Tanabe Y, Tamura N, Miura Y, Shigekawa T, Kawabata H, Baba N, Iguchi H, Takano T. Takahashi M, et al. Among authors: kawabata h. BMC Cancer. 2019 Oct 22;19(1):980. doi: 10.1186/s12885-019-6236-6. BMC Cancer. 2019. PMID: 31640606 Free PMC article.
Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients.
Tanabe Y, Shiraishi S, Hashimoto K, Ikeda K, Nishizawa D, Hasegawa J, Shimomura A, Ozaki Y, Tamura N, Yunokawa M, Yonemori K, Takano T, Kawabata H, Tamura K, Fujiwara Y, Shimizu C. Tanabe Y, et al. Among authors: kawabata h. BMC Cancer. 2020 Apr 16;20(1):325. doi: 10.1186/s12885-020-06834-0. BMC Cancer. 2020. PMID: 32295642 Free PMC article.
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T. Ozaki Y, et al. Among authors: kawabata h. Eur J Cancer. 2022 Aug;171:193-202. doi: 10.1016/j.ejca.2022.05.014. Epub 2022 Jun 18. Eur J Cancer. 2022. PMID: 35728379 Free article. Clinical Trial.
784 results